SE0302304D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0302304D0
SE0302304D0 SE0302304A SE0302304A SE0302304D0 SE 0302304 D0 SE0302304 D0 SE 0302304D0 SE 0302304 A SE0302304 A SE 0302304A SE 0302304 A SE0302304 A SE 0302304A SE 0302304 D0 SE0302304 D0 SE 0302304D0
Authority
SE
Sweden
Prior art keywords
novel compounds
sulphonamides
pyrazinyl
formula
treatment
Prior art date
Application number
SE0302304A
Other languages
English (en)
Swedish (sv)
Inventor
Andrew Baxter
Nicholas Kindon
Michael Stocks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302304A priority Critical patent/SE0302304D0/xx
Publication of SE0302304D0 publication Critical patent/SE0302304D0/xx
Priority to JP2006524604A priority patent/JP2007503432A/ja
Priority to AT04775333T priority patent/ATE411984T1/de
Priority to EP04775333A priority patent/EP1660461B1/en
Priority to PCT/SE2004/001227 priority patent/WO2005021513A1/en
Priority to ES04775333T priority patent/ES2314445T3/es
Priority to DE602004017332T priority patent/DE602004017332D1/de
Priority to US10/570,178 priority patent/US20070093491A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
SE0302304A 2003-08-27 2003-08-27 Novel compounds SE0302304D0 (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE0302304A SE0302304D0 (sv) 2003-08-27 2003-08-27 Novel compounds
JP2006524604A JP2007503432A (ja) 2003-08-27 2004-08-25 新規な縮合ｎ−ピラジニル−スルホンアミドおよびケモカイン介在疾患の処置におけるそれらの使用
AT04775333T ATE411984T1 (de) 2003-08-27 2004-08-25 Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
EP04775333A EP1660461B1 (en) 2003-08-27 2004-08-25 Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases
PCT/SE2004/001227 WO2005021513A1 (en) 2003-08-27 2004-08-25 Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases
ES04775333T ES2314445T3 (es) 2003-08-27 2004-08-25 Nuevas n-pirazinil-fulfonamidas condensadas y su uso en el tratamiento de enfermedades mediadas por quimioquinas.
DE602004017332T DE602004017332D1 (de) 2003-08-27 2004-08-25 Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
US10/570,178 US20070093491A1 (en) 2003-08-27 2004-08-25 Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302304A SE0302304D0 (sv) 2003-08-27 2003-08-27 Novel compounds

Publications (1)

Publication Number Publication Date
SE0302304D0 true SE0302304D0 (sv) 2003-08-27

Family

ID=28673200

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302304A SE0302304D0 (sv) 2003-08-27 2003-08-27 Novel compounds

Country Status (8)

Country Link
US (1) US20070093491A1 (OSRAM)
EP (1) EP1660461B1 (OSRAM)
JP (1) JP2007503432A (OSRAM)
AT (1) ATE411984T1 (OSRAM)
DE (1) DE602004017332D1 (OSRAM)
ES (1) ES2314445T3 (OSRAM)
SE (1) SE0302304D0 (OSRAM)
WO (1) WO2005021513A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
AU2006302179C1 (en) 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
WO2007063935A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 芳香族化合物
TW200730512A (en) * 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
US8614215B2 (en) * 2007-02-22 2013-12-24 Merck Serono Sa Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks)
US7940543B2 (en) * 2008-03-19 2011-05-10 Nanya Technology Corp. Low power synchronous memory command address scheme
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
PT2374802E (pt) 2008-11-10 2014-07-10 Kyowa Hakko Kirin Co Ltd Inibidor de produção de quinurenina
TWI535442B (zh) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
JP2013540141A (ja) 2010-10-20 2013-10-31 メルク セローノ ソシエテ アノニム ジュネーブ 置換ｎ−（３−アミノ−キノキサリン−２−イル）−スルホンアミドおよびそれらの中間体ｎ−（３−クロロ−キノキサリン−２−イル）スルホンアミドを調製する方法
EP2781517B1 (en) * 2011-11-09 2017-10-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
KR101102377B1 (ko) * 2011-11-11 2012-01-05 주식회사 에네스코 터빈로터 초음파 탐상용 스캐너
US20260070891A1 (en) * 2022-08-30 2026-03-12 Kyowa Kirin Co., Ltd. Method for producing quinoxaline derivative

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1135471B (de) * 1960-07-30 1962-08-30 Basf Ag Verfahren zur Herstellung von 3-Chlorchinoxalinderivaten
FR1310181A (OSRAM) * 1960-12-21 1963-03-06
FR1495549A (OSRAM) * 1966-08-08 1967-12-20
CS156880B1 (OSRAM) * 1972-02-09 1974-08-23
EP0215200B1 (en) * 1985-06-24 1992-09-09 Merck & Co. Inc. Use of sulfanilamido quinoxalines in the treatment of neoplastic diseases
US5529999A (en) * 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
AUPN842196A0 (en) * 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2003051870A1 (en) * 2001-12-18 2003-06-26 Astrazeneca Ab Novel compounds
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
AU2003252478A1 (en) * 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof

Also Published As

Publication number Publication date
US20070093491A1 (en) 2007-04-26
WO2005021513A1 (en) 2005-03-10
JP2007503432A (ja) 2007-02-22
DE602004017332D1 (de) 2008-12-04
ES2314445T3 (es) 2009-03-16
EP1660461A1 (en) 2006-05-31
ATE411984T1 (de) 2008-11-15
EP1660461B1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
ATE461217T1 (de) Glp-1-verbindungen
SE0301700D0 (sv) Novel compounds
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
UA85559C2 (en) Aminobenzophenone compounds
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
NO20034056D0 (no) Proliferative sykdommer
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE448232T1 (de) Substituierte heterozyklen
ATE312096T1 (de) Neue verbindungen
BG66080B1 (bg) Заместени тиоацетамиди
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
NO20055741L (no) Nye kjemiske forbindelser
SE0102716D0 (sv) Novel compounds
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
NO20053903D0 (no) Nukleotidlipidesterderivater.
NO20005548D0 (no) Mykobakterieinhibitorer
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
NO20053562L (no) Nye aminobenzofenonforbindelser
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.